Showing 1-5 of 35 payers:
OM1 and Medtronic Partner on Propel Study to Assess Long-term Outcomes for Patients With Chronic Rhinosinusitis

Utilizing clinical data from electronic health records related to endoscopic sinus surgeries, Medtronic and OM1 found PROPEL devices result in fewer postoperative care needs in chronic rhinosinusitis patients   April 09, 2024 09:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–OM1, the leading AI and insights-driven technology and data company specializing in personalized medicine, evidence generation, and[…]

Expert Praises Proposed Federal Rule to Strengthen Behavioral Health Parity

HealthLeaders Christopher Cheney August 1, 2023 Read the full article >> A new proposal from the Biden administration to strengthen parity for behavioral health services with physical health services is a step in the right direction, according to Carl Marci, MD, a psychiatrist at Massachusetts General Hospital and an assistant professor of psychiatry at Harvard Medical School.[…]

12 New Ways Companies Are Helping to Improve Adherence

PM360 July 13, 2023 Read the full article>> Reasons for Discontinuation (RfD) Analytics Report An estimated 50% of patients with a prescription for a chronic condition stop taking it within the first year, leading to worse outcomes and nearly $250 billion lost revenue annually for the pharmaceutical industry. To combat this, OM1 launched its Reasons for Discontinuation[…]

Many Female Arthritis Drug Users Face Restrictions After Dobbs

Bloomberg Law Publish Date: November 14, 2022 Read the Full Article >> More than half of women ages 15 to 49 who use a common arthritis drug risk losing access under restrictive state abortion laws, according to a new study based on nationwide health-care data. The analysis, published Saturday in the Arthritis & Rheumatology Journal, found[…]

1 2 3 … 7